⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL28073004 | 1.00 | — | — | |
| Trimethylammonium SCHEMBL16052296 | 0.94 | — | — | |
| Trimethylammonium SCHEMBL27256477 | 0.94 | — | — | |
| Trimethylammonium SCHEMBL27754106 | 0.94 | — | — | |
| Trimethylammonium SCHEMBL28579353 | 0.94 | — | — | |
| Trimethylammonium SCHEMBL27695915 | 0.89 | — | — | |
| Trimethylammonium SCHEMBL27258438 | 0.89 | — | — | |
| Trimethylammonium SCHEMBL27257424 | 0.89 | — | — | |
| Trimethylammonium SCHEMBL28762421 | 0.85 | — | — | |
| Trimethylammonium SCHEMBL27573890 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111253464-B | Gamma-glutamyl transpeptidase targeted molecular probe and preparation method and application thereof | 江苏省原子医学研究所 | 2022-02-01 | — | — | CN | claimed |
| CN-111253464-A | Gamma-glutamyl transpeptidase targeted molecular probe and preparation method and application thereof | 江苏省原子医学研究所 | 2020-06-09 | — | — | CN | claimed |
| WO-2015135082-A1 | BRADYKININ RECEPTOR B1 TARGETING PROBES | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-09-17 | — | — | WO | claimed |
| US-12427209-B2 | Dual mode 18F-labelled theranostic compounds and uses thereof | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-09-30 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| CN-118338916-A | Multifunctional compounds for use in medical imaging and therapy | 安特络手术解决方案公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2024129715-A1 | COMPOUNDS AND COMPOSITION FOR TARGETING TP53-Y220C MUTANTS | FLARE THERAPEUTICS INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-20 | — | — | US | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-11866426-B2 | Benzothiazole compounds and uses thereof | INCYTE CORPORATION (US) | 2024-01-09 | — | — | US | disclosed |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| EP-2516433-B1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20130345200-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| EP-2516433-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | Array Biopharma, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2011014520-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |